leadf
logo-loader

Highlight Therapeutics

Receive alerts
Market:
Unlisted (UK)
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy, a very large market opportunity.

Snapshot

  • Highlight Therapeutics starts recruiting for metastatic melanoma drug trial
  • Highlight Therapeutics: on a mission to extend benefits of immuno-oncology drugs
  • Highlight Therapeutics presents latest progress on metastatic melanoma treatment trial

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Highlight Therapeutics: on a mission to extend benefits of immuno-oncology drugs

The company’s lead product is being tested in two clinical trials, both of which are at the Phase II stage in collaboration with Merck & Co’s (MSD) Keytruda immunotherapy

on 29/1/21